The Competition Tribunal dismissed a lawsuit by Laboratorios Recalcine S.A. against Roche Chile Limitada in all its parts, since the conducts that Recalcine reported were not proven in the proceeding, and no evidence from which the conducts could be inferred was presented.
Laboratorios Recalcine filed a lawsuit against Roche Chile Limitada, stating that the defendant had carried out various actions that tended to illegitimately prevent or hinder the introduction of the drug “Reditux”, manufactured by Recalcine for treating a type of cancer –Non-Hodgkin Lymphoma– and rheumatoid arthritis, through a smear campaign that would have been orchestrated in different levels, thus infringing Article 3 letters b) and c) of Decree Law N° 211.